Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Short term Debt: 2023-2025

Historic Short term Debt for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to $4.5 million.

  • BioLineRx's Short term Debt fell 57.97% to $4.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $4.5 million, marking a year-over-year decrease of 57.97%. This contributed to the annual value of $4.5 million for FY2024, which is 42.42% up from last year.
  • Latest data reveals that BioLineRx reported Short term Debt of $4.5 million as of Q2 2025, which was down 4.38% from $4.7 million recorded in Q1 2025.
  • In the past 5 years, BioLineRx's Short term Debt registered a high of $10.7 million during Q2 2024, and its lowest value of $2.6 million during Q1 2023.
  • In the last 3 years, BioLineRx's Short term Debt had a median value of $4.1 million in 2024 and averaged $5.0 million.
  • In the last 5 years, BioLineRx's Short term Debt soared by 246.20% in 2024 and then slumped by 57.97% in 2025.
  • Over the past 3 years, BioLineRx's Short term Debt (Quarterly) stood at $3.1 million in 2023, then skyrocketed by 42.42% to $4.5 million in 2024, then slumped by 57.97% to $4.5 million in 2025.
  • Its Short term Debt was $4.5 million in Q2 2025, compared to $4.7 million in Q1 2025 and $4.5 million in Q4 2024.